Therapeutic relevance of breast cancer micrometastases in sentinel lymph nodes

British Journal of Surgery

Volumn 89, Issue 12, 2002, Pages 1505-1515

  Noguchi, M ^a  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; EOSIN; HEMATOXYLIN;

ANTIGEN EXPRESSION; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL ISOLATION; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; ERADICATION THERAPY; FOLLOW UP; FROZEN SECTION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAOPERATIVE PERIOD; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; OCCULT CANCER; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY ANALYSIS; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR CELL;

AXILLA; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRAOPERATIVE CARE; LYMPHATIC METASTASIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE BIOPSY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036446005     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.2002.02294.x     Document Type: Review

References (90)

1. Fisher ER, Sass R, Fisher B, collaborating NSABP investigators. Pathological findings from the National Surgical Adjuvant Project for Breast Cancer (Protocol no. 4): Discriminants for tenth year treatment failure. Cancer 1984; 53 (Suppl): 712-23.
2. McGuire WL, Abeloff MD, Fisher B, Glick JH, Henderson IG, Osborne CK. Adjuvant therapy in node-negative breast cancer. A panel discussion. Breast Cancer Res Treat 1989; 13: 97-115.
3. Noguchi M, Miyazaki I. Prognostic factors in breast cancer and their controversies. Oncology Report 1994; 1: 1157-63.
4. Dowlatshahi K, Fan M, Bloom KJ, Spitz DJ, Patel S, Snider HC Jr. Occult metastases in the sentinel lymph nodes of patients with early stage breast carcinoma. A preliminary study. Cancer 1999; 86: 990-6.
5. Nasser IA, Lee AKC, Bosari S, Saganich R, Heatley G, Silverman ML. Occult axillary lymph node metastases in 'node-negative' breast carcinoma. Hum Pathol 1993; 24: 950-7.
6. McGuckin MA, Cummings MC, Walsh MD, Hohn BG, Bennett IC, Wright RG. Occult axillary node metastases in breast cancer: Their detection and prognostic significance. Br J Cancer 1996; 73: 88-95.
7. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997; 15: 2345-50.
8. Chu KU, Turner RR, Hansen NM, Brennan MB, Bilchik A, Giuliano AE. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 1999; 229: 536-41.
9. Reynolds C, Mick R, Donohue JH, Grant CS, Farley DR, Callans LS et al. Sentinel lymph node biopsy with metastasis: Can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol 1999; 17: 1720-6.
10. Huvos AG, Hutter RV, Berg JW. Significance of axillary macrometastases and micrometastases in mammary cancer. Ann Surg 1971; 173: 44-6.
11. Dowlatshahi K, Fan M, Snider HC, Habib FA. Lymph node micrometastases from breast carcinoma: Reviewing the dilemma. Cancer 1997; 80: 1188-97.
12. Hermanek P, Hutter RVP, Sobin LH, Wittekind C. International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. Cancer 1999; 86: 2668-73.
13. Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP et al., eds. Breast. In: AJCC Cancer Staging Manual. 5th ed. Philadelphia, Pennsylvania: Lippincott-Raven, 1997: 171-80.
14. Sobin LH, Wittekind C, eds. Breast tumours (ICD-0 CSO). In: TNM Classification of Malignant Tumours. 6th ed. Geneva: Wiley-Liss, 2002: 131-41.
15. Tjan-Heijnen VCG, Bult P, de Widt-Levert LM, Ruers TJ, Beex LVAM. Micro-metastases in axillary lymph nodes: An increasing classification and treatment dilemma in breast cancer due to the introduction of the sentinel lymph node procedure. Breast Cancer Res Treat 2001; 70: 81-8.
16. Page DL, Anderson TJ, Carter BA. Minimal solid tumor involvement of regional and distant sites: When is a metastasis not a metastasis? Cancer 1999; 86: 2589-92.
17. Weaver DL. Sentinel lymph node biopsy in breast cancer: Creating controversy and defining new standards. Adv Anat Pathol 2001; 8: 65-73.
18. Viale G, Maiorano E, Mazzarol G, Zurrida S, Galimberti V, Luini A et al. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer 2001; 92: 1378-84.
19. Rahusen FD, Meijer S, van Diest PJ. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 2000; 231: 615-16 (Letter).
20. Black RB, Roberts MM, Stewart HJ, Prescott R, Cant ELM, Sumerling MD et al. The search for occult metastases in breast cancer: Does it add to established staging methods? Aust N Z J Surg 1980; 50: 574-9.
21. Fisher ER, Palekar A, Rockette H, Redmond C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project (Protocol no. 4). V. Significance of axillary nodal micro- and macrometastases. Cancer 1978; 42: 2032-8.
22. International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990; 335: 1565-8.
23. Chen Z-L, Wen D-R, Coulson WF, Giuliano AE, Cochran AJ. Occult metastases in the axillary lymph nodes of patients with breast cancer node negative by clinical and histologic examination and conventional histology. Dis Markers 1991; 9: 239-48.
24. Clare SE, Sener SF, Wilkens W, Goldschmidt R, Merkel D, Winchester DJ. Prognostic significance of occult lymph node metastases in node-negative breast cancer. Ann Surg Oncol 1997; 4: 447-51.
25. de Mascarel I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micro-metastases assessed by two special techniques: Reevaluation with longer follow-up. Br J Cancer 1992; 66: 523-7.
26. Friedman S, Bertin F, Mouriesse H, Benchabat A, Genin J, Sarazin D et al. Importance of tumor cells in axillary node sinus margins ('clandestine' metastases) discovered by serial sectioning in operable breast carcinoma. Acta Oncol 1988; 27: 483-7.
27. Hainsworth PJ, Tjandra JJ, Stillwell RG, Machet D, Henderson MA, Rennie GC et al. Detection and significance of occult metastases in node-negative breast cancer. Br J Surg 1993; 80: 459-63.
28. Neville AM, Price KN, Gelber RD, Goldhirsch A. Axillary node micrometastases and breast cancer. Lancet 1991; 337: 1110 (Letter).
29. Trojani M, de Mascarel I, Bonichon F, Coindre JM, Delsol G. Micrometastases to axillary lymph nodes from carcinoma of breast: Detection by immunohistochemistry and prognostic significance. Br J Cancer 1987; 55: 303-6.
30. Cote RJ, Peterson HF, Chaiwun B, Gelber RD, Goldhirsh A, Castiglione-Gertsch M et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 1999; 354: 896-900.
31. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CRM et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000; 342: 525-33.
32. Turner RR, Chu KU, Qi K, Botnick LE, Hansen NM, Glass EC et al. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast cancer in a sentinel lymph node. Cancer 2000; 89: 574-81.
33. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 966-78.
34. van Diest PJ, Peterse HL, Borgstein PJ, Hoekstra O, Meijer CJLM. Pathological investigation of sentinel lymph nodes. Eur J Nucl Med 1999; 26(Suppl): S43-9.
35. Snider H, Dowlatshahi K, Fan M, Bridger WM, Rayudu G, Oleske D. Sentinel node biopsy in the staging of breast cancer. Am J Surg 1998; 176: 305-10.
36. Jannink I, Fan M, Nagy S, Rayudu G, Dowlatshahi K. Serial sectioning of sentinel nodes in patients with breast cancer: A pilot study. Ann Surg Oncol 1998; 5: 310-14.
37. Turner RR, Ollila DW, Krasne DL, Giuliano A. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997; 226: 271-8.
38. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995; 222: 394-401.
39. Turner RR, Ollila DW, Stern S, Giuliano AE. Optimal histopathologic examination of the sentinel lymph node for breast carcinoma staging. Am J Surg Pathol 1999; 23: 263-7.
40. Czerniecki BJ, Scheff AM, Callans LS, Spitz FR, Bedrosian I, Conant EF et al. Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma. Cancer 1999; 85: 1098-103.
41. Schreiber RH, Pendas S, Ku NN, Reintgen DS, Shons AR, Berman C et al. Microstaging of breast cancer patients using cytokeratin staining of the sentinel lymph node. Ann Surg Oncol 1999; 6: 95-101.
42. Liu LH, Siziopikou KP, Gabram S, McClatchey KD. Evaluation of axillary sentinel lymph node biopsy by immunohistochemistry and multilevel sectioning in patients with breast carcinoma. Arch Pathol Lab Med 2000; 124: 1670-3.
43. Gemignani ML, Cody HS III, Fey JV, Tran KN, Venkatraman E, Borgen PI. Impact of sentinel lymph node mapping on relative charges in patients with early-stage breast cancer. Ann Surg Oncol 2000; 7: 575-80.
44. Fisher ER, Swamidoss S, Lee CH, Rockette H, Redmond C, Fisher B. Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 1978; 42: 2025-31.
45. Torrenga H, Rahusen FD, Meijer S, Borgstein PJ, van Diest PJ. Sentinel node investigation in breast cancer: Detailed analysis of the yield from step sectioning and immunohistochemistry. J Clin Pathol 2001; 54: 550-2.
46. Meyer JS. Sentinel lymph node biopsy: Strategies for pathologic examination of the specimen. J Surg Oncol 1998; 69: 212-18.
47. Turner RR, Giuliano AE. Intraoperative pathologic examination of the sentinel lymph node. Ann Surg Oncol 1999; 5: 670-2.
48. Chao C, Wong SL, Ackermann D, Simpson D, Carter MB, Brown CM et al. Utility of intraoperative frozen section analysis of sentinel lymph nodes in breast cancer. Am J Surg 2001; 182: 609-15.
49. Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M et al. Sentinel node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997; 349: 1864-7.
50. Noguchi M, Motomura K, Imoto S, Miyauchi M, Sato K, Iwata H et al. A multicenter validation study of sentinel lymph node biopsy by the Japanese Breast Cancer Society. Breast Cancer Res Treat 2000; 63: 31-40.
51. Veronesi U, Paganelli G, Viale G, Galimberti V, Luini A, Zurrida S et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: Results in a large series. J Natl Cancer Inst 1999; 91: 368-73.
52. Noguchi M, Tsugawa K, Kawahara F, Bando E, Miwa K, Minato H et al. Dye-guided sentinel lymphadenectomy in clinically node-negative and node-positive breast cancer patients. Breast Cancer 1998; 5: 381-7.
53. Tanis PJ, Boom RPA, Koops HS, Faneyte IF, Peterse JL, Nieweg OE et al. Frozen section investigation of the sentinel node in malignant melanoma and breast cancer. Ann Surg Oncol 2001; 8: 222-6.
54. Canavese G, Gipponi M, Catturich A, Di Somma C, Vecchio C, Rosato F et al. Sentinel lymph node mapping opens a new perspective in the surgical management of early-stage breast cancer: A combined approach with vital blue dye lymphatic mapping and radioguided surgery. Semin Surg Oncol 1998; 15: 272-7.
55. Noguchi M, Tsugawa K, Miwa K, Yokoyama K, Nakajima K, Michigishi T et al. Sentinel lymph node biopsy in breast cancer using blue dye with or without isotope localization. Breast Cancer 2000; 7: 287-96.
56. Viale G, Bosari S, Mazzarol G, Galimberti V, Luini A, Veronesi P et al. Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. Cancer 1999; 85: 2433-8.
57. Rubio IT, Korourian S, Cowan C, Krag DN, Colvert M, Klimberg VS. Use of touch preps for intraoperative diagnosis of sentinel lymph node metastases in breast cancer. Ann Surg Oncol 1998; 5: 689-94.
58. Van Diest PJ, Torrenga H, Borgstein PJ, Pijpers R, Bleichrodt RP, Rahusen FD et al. Reliability of intraoperative frozen section and imprint cytological investigation of sentinel lymph nodes in breast cancer. Histopathology 1999; 35: 14-18.
59. Ratanawichitrasin A, Biscotti CV, Levy L, Crowe JP. Touch imprint cytological analysis of sentinel lymph nodes for detecting axillary metastases in patients with breast cancer. Br J Surg 1999; 86: 1346-8.
60. Motomura K, Inaji H, Komoike Y, Kasugai T, Nagumo S, Noguchi S et al. Intraoperative sentinel lymph node examination by imprint cytology and frozen sectioning during breast surgery. Br J Surg 2000; 87: 597-601.
61. Cserni G. The potential value of intraoperative imprint cytology of axillary sentinel lymph nodes in breast cancer patients. Am Surg 2001; 67: 86-91.
62. Kataoka A, Mori M, Sadanaga N, Ueno H, Tsuji K, Rai Y et al. RT-PCR detection of breast cancer cells in sentinel lymph nodes. Int J Oncol 2000; 16: 1147-52.
63. Wascher RA, Bostick PJ, Huynh KT, Turner R, Qi K, Giuliano AE et al. Detection of MAGE-A3 in breast cancer patients' sentinel lymph nodes. Br J Cancer 2001; 85: 1340-6.
64. Branagan G, Hughes D, Jeffrey M, Crane-Robinson C, Perry PM. Detection of micrometastases in lymph nodes from patients with breast cancer. Br J Surg 2002; 89: 86-9.
65. Min CJ, Tafra L, Verbanac KM. Identification of superior markers for polymerase chain reaction detection of breast cancer metastases in sentinel lymph nodes. Cancer Res 1998; 58: 4581-4.
66. Leygue E, Snell L, Dotzlaw H, Hole K, Troup S, Hiller-Hitchcock T et al. Mammaglobin, a potential marker of breast cancer nodal metastases. J Pathol 1999; 189: 28-33.
67. Watson MA, Dintzis S, Darrow CM, Voss LE, DiPersio J, Jensen J et al. Mammaglobin expression in primary, metastatic, and occult breast cancer. Cancer Res 1999; 59: 3028-31.
68. Bostick PJ, Chatterjee S, Chi DD, Huynh KT, Giuliano AE, Cote R et al. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol 1998; 16: 2632-40.
69. Hoon DSB, Sarantou T, Doi F, Chi DDJ, Kuo C, Conrad AJ et al. Detection of metastatic breast cancer by beta-HCG polymerase chain reaction. Int J Cancer 1996; 69: 369-74.
70. Ross MI. Sentinel node dissection in early-stage breast cancer: Ongoing prospective randomized trials in the USA. Ann Surg Oncol 2001; 8(Suppl): S77-81.
71. Noguchi M, Katev N, Miyazaki I. Diagnosis of axillary lymph node metastases in patients with breast cancer. Breast Cancer Res Treat 1996; 40: 283-93.
72. Cody HS III. Sentinel lymph node mapping in breast cancer. Breast Cancer 1999; 6: 13-22.
73. Noguchi M. Sentinel lymph node biopsy and breast cancer. Br J Surg 2002; 89: 21-34.
74. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-85.
75. Clarke D, Khonji NI, Mansel RE. Sentinel node biopsy in breast cancer: ALMANAC trial. World J Surg 2001; 25: 819-22.
76. Krag D. Why perform randomized clinical trials for sentinel node surgery for breast cancer? Am J Surg 2001; 182: 411-13.
77. European Organisation for Research on Treatment of Cancer (EORTC) Breast Cancer Cooperative Group. EORTC Protocol 10981: After Mapping of the Axilla: Radiotherapy or Surgery (AMAROS). Brussels: EORTC Data Center, 1999.
78. O'Hea BJ, Hill ADK, El-Shirbiny AM, Yeh SDJ, Rosen PP, Coit DG et al. Sentinel lymph node biopsy in breast cancer: Initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 1998; 186: 423-7.
79. Galimberti V, Zurrida S, Zucali P, Luini A. Can sentinel node biopsy avoid axillary dissection in clinically node-negative breast cancer patients? Breast 1998; 7: 8-10.
80. Bedrosian I, Reynolds C, Mick R, Callans LS, Grant CS, Donohue JH et al. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer 2000; 88: 2540-5.
81. Olson JA Jr, Fey J, Winawer J, Borgen PI, Cody HS III, van Zee KJ et al. Sentinel lymphadenectomy accurately predicts nodal status in T2 breast cancer. J Am Coll Surg 2000; 191: 593-9.
82. Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000; 18: 2553-9.
83. Veronesi U, Galimberti V, Zurrida S, Pigatto F, Veronesi P, Robertson C et al. Sentinel lymph node biopsy as an indicator for axillary dissection in early breast cancer. Eur J Cancer 2001; 37: 454-8.
84. Schrenk P, Hatzl-Griesenhofer M, Shamiyeh A, Waynad W. Follow-up of sentinel node negative breast cancer patients without axillary lymph node dissection. J Surg Oncol 2001; 77: 165-70.
85. Roumen RMH, Kuijt GP, Liem IH, van Beek MWPM. Treatment of 100 patients with sentinel node-negative breast cancer without further axillary dissection. Br J Surg 2001; 88: 1639-43.
86. Noguchi M. Sentinel lymph node biopsy in breast cancer: An overview of the Japanese experience. Breast Cancer 2001; 8: 184-94.
87. Fisher B, Redmond C. Systemic therapy in node-negative patients: Updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst Monogr 1992; 11: 105-16.
88. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 Randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 71-85.
89. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998; 351: 1451-67.
90. Weaver DL, Krag DN, Ashikaga T, Harlow SP, O'Connell M. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: A multicenter study. Cancer 2000; 88: 1099-107.